Pituitary metastases: a case series and scoping review

Pituitary. 2023 Oct;26(5):538-550. doi: 10.1007/s11102-023-01349-w. Epub 2023 Sep 12.

Abstract

Purpose: To understand the natural history and optimal treatment strategy for pituitary gland metastasis.

Methods: We performed both a retrospective chart review of patients treated at our institution and a scoping review of the topic.

Results: The retrospective review identified seven patients with an average age of 59.6 years. Primary histologies included breast cancer (4), melanoma (1), renal cell carcinoma (1), and sarcoma (1). Two patients had anterior pituitary endocrine dysfunction, one of whom was the only patient with visual symptoms. All patients were treated with radiosurgery and two also underwent surgical resection. Overall survival ranged from 6.5 to 117 months. Literature review identified 166 patients from 71 studies. The most common primary cancer was lung (27.7%), followed by breast (18.7%) and renal (14.5%) cancer. 107 presented with endocrine dysfunction, including 41 cases of diabetes insipidus and 55 cases of hypopituitarism. 110 presented with visual compromise. 107 patients received radiotherapy, 96 underwent surgical resection and 44 received systemic chemotherapy/immunotherapy. Surgery was significantly associated with an increased likelihood of vision improvement and a decreased likelihood of endocrine normalization. Radiographic regression predicted visual improvement. Median overall survival was 9.9 months (range: 0.2-96).

Conclusions: This scoping review showed that both radiosurgery and surgical resection have been frequently used to treat pituitary metastases with good response. Vision improvement is more likely to happen following surgical resection, likely at the expense of endocrine dysfunction. Despite treatment and radiographic response, patient survival remains less than a year.

Keywords: Case series; Metastasis; Pituitary; Scoping review; Treatment.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell*
  • Diabetes Insipidus*
  • Humans
  • Kidney Neoplasms* / pathology
  • Kidney Neoplasms* / surgery
  • Middle Aged
  • Pituitary Neoplasms* / surgery
  • Radiosurgery*
  • Retrospective Studies
  • Treatment Outcome